Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

trol of Tissue Contouring with an

Extracellular pH-Modulated Enzyme" pre-clinical data

-- American Diabetes Association - June 6-10th - presentation on

"Pharmacokinetics and Glucodynamics of an Insulin Analog Injected with

Recombinant Human Hyaluronidase" Phase I clinical data

-- 6th World Congress of the International Academy of Cosmetic

Dermatology - June 18-20th - podium presentation of "Temporal-Spatial

Control of Tissue Contouring with an Extracellular pH-Modulated

Enzyme" expanded pre-clinical data

First Quarter 2008 Financial Results

-- Net loss for the first quarter of 2008 was $10.0 million, or $0.13 per

share, compared with a net loss for the first quarter of 2007 of

$3.4 million, or $0.05 per share.

-- Revenues for the first quarter of 2008 were $1.8 million, compared

with $810,000 for the first quarter of 2007. Cumulase product sales

for the first quarter of 2008 were $127,000, compared with $171,000

for the first quarter of 2007. Revenues under collaborative

agreements for the first quarter of 2008 were $1.7 million, compared

with $623,000 for the first quarter of 2007. Revenues under

collaborative agreements in 2008 primarily consisted of the

amortization of upfront fees received from Baxter and Roche of

$588,000 and research and development reimbursements from Baxter of

$452,000 and Roche of $624,000.

-- Research and development expenses for the first quarter of 2008 were

$8.4 million, compared with $2.8 million for the first quarter of

2007, reflecting increased compensation expenses including share-based

compensation expenses, research and development spending on our

Insulin, Bisphosphonates, and PEG PH20 clinical and pre-clinical

programs, and production costs associated with the manu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Nov. 3 Portola,Pharmaceuticals, a biopharmaceutical company ... cardiovascular and inflammatory,diseases, and cancer, today announced ... large Phase II clinical trial of betrixaban, ... for stroke prevention in patients with,atrial fibrillation ...
... Phase 2, clinical trial indicate statistically significant reduction in recurrences ... ... PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/,-- Medarex, Inc. ... University of Massachusetts Medical School (UMMS) today,announced that a Phase 2 ...
... Nov. 3 Cepheid (Nasdaq:,CPHD) today announced ... agreement to,acquire Stretton Scientific Limited, a privately ... equipment based in,Stretton, England. Stretton Scientific currently ... life science products, to,a broad group of ...
Cached Biology Technology:Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 2Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 3Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 4Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 5Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) 6Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 2Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific 3
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... planktonic microbes living throughout the water column in the ... specialization of microbial communities at each depth--ranging from 40 ... information stored in the genomes of entire microbial communities, ... marine ecosystem," said MIT's Ed DeLong, who led the ...
... Center scientists have demonstrated a new technology that accurately ... coli bacteria. , The unique technology uses a protein ... system that also includes a silicon chip and a ... an article on the technology in its February issue. ...
... succeeded in growing mature taste receptor cells outside the body ... keep the cells alive for a prolonged period of time. ... of new opportunities to increase scientists' understanding of the sense ... disease. , "We have an important new tool to help ...
Cached Biology News:Vaccine provides 100 percent protection against avian flu virus in animal study 2Vaccine provides 100 percent protection against avian flu virus in animal study 3Rochester scientists develop fast-working biosensor 2Living taste cells produced outside the body 2Living taste cells produced outside the body 3
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... 3T3 cells were cultured in DMEM with 4 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: